Furosemide as a Fetal Growth Promoter

Czeizel, Andr̀ew E.; Rockenbauer, Magda; Mosonyi, Attila

doi:10.2165/00044011-200020010-00007

Cited by 3 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 Since the risk of adverse effects may be heightened in this population, more frequent laboratory monitoring (e.g., electrolyte levels and renal function) is warranted. 30,[32][33][34] Patients should closely monitor their weight in order to prevent overdiuresis. Likewise, clinicians should assess physical examination findings and evaluate for symptoms of volume overload, as weight gain and edema may be influenced by the evolving pregnancy.…”

Section: Pregnancy and Peripartum Cardiomyopathymentioning

confidence: 99%

“…Furosemide use during pregnancy was retrospectively reviewed in a national registry of 38,151 women who had children without congenital abnormalities . Most women received the drug during their third trimester, and 450 infants were exposed to furosemide.…”

Section: Pharmacologic Managementmentioning

confidence: 99%

“…Loop diuretics should be used to alleviate symptoms in patients with PPCM and HF symptoms . Since the risk of adverse effects may be heightened in this population, more frequent laboratory monitoring (e.g., electrolyte levels and renal function) is warranted . Patients should closely monitor their weight in order to prevent overdiuresis.…”

Section: Summary Of Recommendations For Management Of Peripartum Cardmentioning

confidence: 99%

“…Furosemide use during pregnancy was retrospectively reviewed in a national registry of 38,151 women who had children without congenital abnormalities. 33 Most women received the drug during their third trimester, and 450 infants were exposed to furosemide. Birth weight was significantly higher among those exposed to furosemide, resulting in a 60% reduction in low-birth weight infants.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Safe and Effective Use of Pharmacologic and Device Therapy for Peripartum Cardiomyopathy

et al. 2016

View full text Add to dashboard Cite

Peripartum cardiomyopathy (PPCM) is an uncommon, idiopathic complication of pregnancy associated with significant (10-30%) mortality. The disease occurs late in pregnancy or in the months following delivery, resulting in reduced systolic function and heart failure (HF) symptoms. Limited direction is provided for the management of PPCM, and the safe and effective use of medications in pregnant and breastfeeding women with PPCM presents a unique challenge. Although several HF therapies in pregnant and lactating women are supported by robust evidence, evidence to support the use of other therapies is significantly lacking. Current guidelines recommend treatment as in other forms of HF with reduced left ventricular ejection fraction (LVEF) but with consideration for the important nuances in this population as well as the unique and potential teratogenic effects of these therapies. Since most patients with PPCM recover their LVEF, the duration of therapy is currently unknown and warrants further study. We review the available literature surrounding pharmacologic and device therapy for PPCM and provide insight into managing patients with the condition.

show abstract

Section: Pregnancy and Peripartum Cardiomyopathymentioning

confidence: 99%

Section: Pharmacologic Managementmentioning

confidence: 99%

Section: Summary Of Recommendations For Management Of Peripartum Cardmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Safe and Effective Use of Pharmacologic and Device Therapy for Peripartum Cardiomyopathy

et al. 2016

View full text Add to dashboard Cite

show abstract

Current Awareness

2000

Prenat. Diagn.

View full text Add to dashboard Cite

Current Awareness

2000

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Furosemide as a Fetal Growth Promoter

Cited by 3 publications

References 14 publications

Safe and Effective Use of Pharmacologic and Device Therapy for Peripartum Cardiomyopathy

Safe and Effective Use of Pharmacologic and Device Therapy for Peripartum Cardiomyopathy

Current Awareness

Current Awareness

Contact Info

Product

Resources

About